Join a clinical trial
Clinical trials are research studies involving people. They test ways to treat and prevent disease and are the gold standard tests for decisions on whether a treatment works and if it is more effective than an alternative treatment.
We conduct trials into chronic respiratory conditions, including asthma, COPD, bronchiectasis, idiopathic pulmonary fibrosis (IPF) and cystic fibrosis.
Below lists a number of clinical trials you may be eligible for. Each trial is different, so please read our FAQs to find out more.
The study aims to evaluate the effectiveness and safety of Tezepelumab in patients with asthma.
- Aged between 18-80 with a diagnosis of asthma made by a doctor
- Use of two asthma inhalers daily
- At least two asthma flare-ups in the last 12 months
- Current smokers excluded
You will be required to attend up to 17 visits to Sir Charles Gairdner Hospital for approximately 16 months.
Alpha1 Antitrypsin Deficiency
- 18- 70 years old
- Diagnosis of Alpha 1 Antitrypsin Deficiency with evidence of emphysema.
- No flare up of the chest in the last 5 weeks prior to the first visit.
- No cancer in last 5 years
You will be required to come once a week for 3 years for treatment including health checks to Sir Charles Gairdner Hospital.
CT scans of your lungs will be required on 5 occasions throughout the trial
The study aims to evaluate the effect of INS1007 (study drug) compared with no study drug on time to first pulmonary exacerbation (chest flare up) over the 24-week treatment period.
- Aged between 18 and 85 with a diagnosis of non-cystic fibrosis bronchiectasis.
- At least two flare-ups of your bronchiectasis requiring antibiotic treatment in the last 12 months.
You will be required to attend up to 10 visits to Sir Charles Gairdner Hospital for up to approximately 8 months.
The aim of this study is to evaluate the effect of CC-90001 in 200 mg tablet and 400 mg tablet, taken once daily compared with a placebo, on lung function after 24 weeks of treatment in patients with Idiopathic Pulmonary Fibrosis (IPF).
- Aged 40 years or older
- Have had a diagnosis of IPF within the last 4 years
- Forced Vital Capacity (FVC) ≥45% at screening
- Percent predicted diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 30% and ≤ 85% predicted at Screening
- Able to walk ≥150m during the 6-minute walk test at screening
- Additional inclusion criteria apply
You will be required to attend a monthly visit to Sir Charles Gairdner Hospital for approximately 14 months. You will receive study treatment/placebo (2:1) in the form of oral tablets for approximately 52 weeks.
Pulmonary Arterial Hypertension
This study is to determine whether there are any health benefits to be gained from Apixaban, an anticoagulant medication, in patients with Systemic Sclerosis related Pulmonary Arterial Hypertension ( SSc – PAH) who are already prescribed advanced Pulmonary Arterial Hypertension (PAH) therapy.
- Aged 18 – 75 years
- Systemic Sclerosis related
- Pulmonary Arterial Hypertension (SSc-PAH) diagnosed by a right heart catheterization
You will be required to attend at least 9 visits across a three year period at Sir Charles Gairdner Hospital. There are also monthly phone calls to assess any changes in your health.